Age-related cognitive decline
Not recommended
Phosphatidylserine is an OTC supplement with one of the loudest US marketing histories. The in 2003 granted a qualified health claim worded verbatim «consumption of phosphatidylserine may reduce the risk of cognitive dysfunction in the elderly, very limited supporting science». The «very limited evidence» disclaimer is part of the claim itself, not a footnote. The Kato-Kataoka RCT (J Clin Biochem Nutr 2010) of soy PS in 78 older adults with memory complaints at 300 mg/day for 6 months showed a small word-recall improvement; effect size was small and the trial was industry-funded. The 2017 Cochrane attempt at a systematic review of PS in cognitive impairment and dementia found too few quality RCTs to pool. 2018 on mild cognitive impairment does not recommend supplements; no pharmacotherapy slows age-related decline in people without dementia, while lifestyle modification per the FINGER 2015 protocol is effective. If phosphatidylserine was bought instead of seeing a geriatrician for memory complaints, discuss with a doctor; occult depression, B12 deficiency, hypothyroidism and sleep disturbance also impair memory and are treatable.
Sources
- J Clin Biochem Nutr (Kato-Kataoka et al.): Soybean-derived phosphatidylserine in elderly with memory complaints: an RCT (2010)
- Cochrane (Wang et al.): Phosphatidylserine for the treatment of cognitive impairment and dementia (2017)
- AAN: Practice guideline update: Mild cognitive impairment (2018)
- Lancet (Ngandu et al., FINGER trial): A 2-year multidomain intervention of diet, exercise, cognitive training and vascular risk monitoring (FINGER) (2015)